WallStreetZenWallStreetZen

NASDAQ: BLRX
Biolinerx Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BLRX

Based on 1 analyst offering 12 month price targets for Biolinerx Ltd

Min Forecast
$26.00+796.55%
Avg Forecast
$26.00+796.55%
Max Forecast
$26.00+796.55%

Should I buy or sell BLRX stock?

Based on 1 analyst offering ratings for Biolinerx Ltd.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BLRX's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates BLRX as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their BLRX stock forecasts and price targets.

BLRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-31

1 of 1

Forecast return on equity

Is BLRX forecast to generate an efficient return?

Company
N/A
Industry
80.01%
Market
61.99%

Forecast return on assets

Is BLRX forecast to generate an efficient return on assets?

Company
N/A
Industry
22.35%

BLRX earnings per share forecast

What is BLRX's earnings per share in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$4.76
Avg 2 year Forecast
-$6.00

BLRX revenue forecast

What is BLRX's revenue in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
$6.8M-76.4%
Avg 2 year Forecast
$7.7M-73.43%
BLRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BLRX revenue growth forecast

How is BLRX forecast to perform vs Biotechnology companies and vs the US market?

Company
-48.45%
Industry
152.36%
Market
10.68%
BLRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BLRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BLRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BLRX$2.90$26.00+796.55%Buy
NRXS$1.80N/AN/A
IMNN$0.89$21.50+2,321.17%Strong Buy
MRKR$1.20$10.25+754.17%Strong Buy
BRTX$1.71N/AN/A
View Top Biotech Stocks

Biolinerx Stock Forecast FAQ

Is Biolinerx Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BLRX) stock is to Buy BLRX stock.

Out of 1 analyst, 0 (0%) are recommending BLRX as a Strong Buy, 1 (100%) are recommending BLRX as a Buy, 0 (0%) are recommending BLRX as a Hold, 0 (0%) are recommending BLRX as a Sell, and 0 (0%) are recommending BLRX as a Strong Sell.

If you're new to stock investing, here's how to buy Biolinerx stock.

What is BLRX's earnings growth forecast for 2025-2026?

(NASDAQ: BLRX) Biolinerx's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 17.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.64%.

Biolinerx's earnings in 2025 is -$9,221,000.On average, 2 Wall Street analysts forecast BLRX's earnings for 2025 to be -$10,627,185,472, with the lowest BLRX earnings forecast at -$13,395,611,940, and the highest BLRX earnings forecast at -$7,858,759,005.

In 2026, BLRX is forecast to generate -$13,395,611,940 in earnings, with the lowest earnings forecast at -$13,395,611,940 and the highest earnings forecast at -$13,395,611,940.

What is BLRX's revenue growth forecast for 2025-2026?

(NASDAQ: BLRX) Biolinerx's forecast annual revenue growth rate of -48.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 152.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.68%.

Biolinerx's revenue in 2025 is $28,940,000.On average, 2 Wall Street analysts forecast BLRX's revenue for 2025 to be $15,248,671,592, with the lowest BLRX revenue forecast at $5,045,680,497, and the highest BLRX revenue forecast at $25,451,662,686.

In 2026, BLRX is forecast to generate $17,168,709,303 in revenue, with the lowest revenue forecast at $17,168,709,303 and the highest revenue forecast at $17,168,709,303.

What is BLRX's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: BLRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 22.35%.

What is BLRX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BLRX price target, the average BLRX price target is $26.00, with the highest BLRX stock price forecast at $26.00 and the lowest BLRX stock price forecast at $26.00.

The Wall Street analyst predicted that Biolinerx's share price could reach $26.00 by Mar 31, 2026. The average Biolinerx stock price prediction forecasts a potential upside of 796.55% from the current BLRX share price of $2.90.

What is BLRX's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: BLRX) Biolinerx's current Earnings Per Share (EPS) is -$0.01. On average, analysts forecast that BLRX's EPS will be -$4.76 for 2025, with the lowest EPS forecast at -$6.00, and the highest EPS forecast at -$3.52. In 2026, BLRX's EPS is forecast to hit -$6.00 (min: -$6.00, max: -$6.00).

What is BLRX's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: BLRX) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.